PHILADELPHIA, Feb. 16, 2017 /PRNewswire-USNewswire/ -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnologycompany harnessing the power of the immune system to find a better treatment for triple negative breast cancer (TNBC), announced today their completion of the YEi Start in France program.
The YEi Start in
"It was an honor to be included among the eight YEi laureates in 2016," said ImMAGE Biotherapeutics President and COO Mahesh Narayanan. "During the course of the program, I had the opportunity to meet with influential companies and investors, including potential partners and mentors that can support our potential expansion overseas."
Narayanan visited a number of research and cancer centers that could be potential clinical sites for ImMAGE in the future. Among the centers were Gustave Roussy, a major cancer center in Europe that specializes in breast cancer, especially with early stage clinical trials; EFS, an immunotherapy research center; and CGFL, a research institute that specializes in using imaging to study biodistribution of drugs.
In addition, Narayanan met with companies that have potential to collaborate with ImMAGE, including Onxeo, an orphan oncology drug development company with four drugs currently in the pipeline, and Oncodesign, a preclinical contract research organization.
ImMAGE plans to start collaborating with many of these institutions over the next 12 months. Gustave Roussy and CHUV/CGFL are potential clinical sites for Europe. Oncodesign is a potential collaborator for the non-GLP efficacy studies, while Onxeo might be an early partner for future development of various candidates.
About ImMAGE BiotherapeuticsImMAGE Biotherapeutics Corp. (OTCMKTS: IMMG) was founded in 2015 to harness the power of the human immune system to treat cancer. The company, which has a presence in the Washington, DC and Philadelphia regions, is developing multiple viable candidates to treat triple-negative breast cancer (TNBC) and has progressed from in-vitro trials to animal testing. The immunotherapy market is expected to grow to $9 billion by 2022 and may be used in up to 60% of cases of advanced cancer. Learn more at www.immagebio.com.
CONTACT: Zhi Mou, 1-866-692-2939
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immage-biotherapeutics-closes-out-2016-in-france-as-a-yei-laureate-300408909.html
SOURCE ImMAGE Biotherapeutics
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All